DOCSLIB.ORG

Systemic Anticancer Therapy Drug Interactions Table

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Systemic Anticancer Therapy Drug Interactions Table Systemic Anticancer Therapy Drug Interactions Table Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 1 of 28 This guide is intended to cover the most common interactions involving Systemic Anticancer therapies, e.g. cytotoxic agents, monoclonal antibodies and targeted therapies. Whilst every effort has been made to ensure it is a comprehensive resource, there may be some interactions which have been unintentionally omitted. Please interpret the information contained in this guide in addition to clinical information and performance status. Copyright Northumbria Healthcare NHS Trust & North of England Cancer Network Version 4.1 October 2012 (Date of Review October 2014) Any comments on this document to [email protected] DRUG INTERACTION WITH INFORMATION REFERENCE Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 2 of 28 DRUG INTERACTION WITH INFORMATION REFERENCE Cisplatin Increased risk of pulmonary toxicity when used in combination Clozapine Increased risk of agranulocytosis 1 Possibility of reduced absorption of digoxin tablets-switch to Digoxin liquid Bleomycin Patients receiving bleomycin pre-operatively are at greater risk of developing pulmonary toxicity when oxygen is administered Oxygen at surgery. A reduction in inspired oxygen concentration during 2 operation and post-operatively is recommended Oral anti diabetic drugs Monitor blood glucose levels, hyperglycaemia in is common 3 Clozapine Increased risk of agranulocytosis 1 Bortezomib Potent CYP3A4 inhibitors and inducers (particularly ketoconazole, Closely monitor as may affect plasma concentration of 1, 3 rifampicin, carbamazepine, bortezomib phenytoin and St Johns Wart) Clozapine Increased risk of agranulocytosis 1 Cyclophosphamide serum levels may be increased (& active Cyclophosphamide metabolite decreased) if given within 24 hours of busulfan 4 Itraconazole and Metronidazole Increase in busulfan toxicity 1,3 Busulfan Ketobemidone Increase in busulfan plasma concentration Paracetamol May decrease intravenous busulfan plasma levels 4 Phenytoin Increases busulfan clearance Tioguanine Increased risk of hepatotoxicity 1 Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 3 of 28 DRUG INTERACTION WITH INFORMATION REFERENCE Allopurinol Possible decreased efficacy of capecitabine 5,6 Aluminium and aluminium Small increase in capecitabine toxicity 5 containing antacids Cimetidine Increased plasma concentration 1 Clozapine Increased risk of agranulocytosis 1 Coumarins Enhanced anticoagulant effect, monitor INR regularly Erlotinib Could increase plasma concentration of erlotinib Increased toxicity of capecitabine, maximum tolerated dose is Folinic acid 1,5 reduced. Decreased rate of capecitabine absorption if administered with Capecitabine Food food. Manufacturers recommend administration within 30 minutes of a meal. Maximum tolerated dose of capecitabine is decreased by Interferon Alpha interferon alpha 6 Metronidazole Increased toxicity 1 Phenytoin May lead to increased phenytoin levels 5 Potentially fatal combination – leads to increased Sorivudine and analogues fluoropyrimidine activity Increased photosensitivity risk when topical fluorouracil and 1, 5 Temoporfin temoporfin used concomitantly Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 4 of 28 DRUG INTERACTION WITH INFORMATION REFERENCE Allopurinol Potential for increased risk of toxicity when used in combination Amiodarone Concomitant use may lead to early onset pulmonary toxicity 6 Fluconazole and itraconazole inhibit the metabolism of Azole antifungals cyclophosphamide, leading to increased toxicity Cyclophosphamide serum levels may be increased (and active Busulfan 5 metabolite decreased) if given within 24 hours of busulfan Increased renal toxicity when used in combination or in patients Cisplatin 6 who have had prior treatment with cisplatin Cyclophosphamide Clozapine Increased risk of agranulocytosis 1 Digoxin Reduces absorption of digoxin tablets 1 Potentiated by cyclophosphamide Oral antidiabetic drugs -monitor blood glucose levels 7 Increased risk of toxicity when pentostatin is given with high Pentostatin dose cyclophosphamide Rifampicin Increased metabolism of cyclophosphamide 6 Suxamethonium Enhances effect of suxamethonium 1 Aldesleukin Avoid concomitant use 8 Dacarbazine Clozapine Increased risk of agranulocytosis 1 Cytochrome P450 (CYP1A1, Darcarbazine is metabolised by cytochrome P450, therefore 8 CYP1A2, and CYP2E1) levels may be altered if co-administered with other substrates Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 5 of 28 DRUG INTERACTION WITH INFORMATION REFERENCE Clozapine Increased risk of agranulocytosis 1 Metabolism of docetaxel clearance altered, may lead to CYP3A inducers and inhibitors 9 increased toxicity or reduced efficacy of docetaxel. Docetaxel Lapatinib Increased risk of neutropenia 9 Ritonavir Plasma concentration of docetaxel increased 1 Sorafenib Increases the plasma concentration of docetaxel 1 Amphotericin B Marked increase in nephrotoxicity Reduced absorption of anticonvulsants when administered in Anticonvulsants combination with doxorubicin 10 Anthracyclines and Cardiotoxic Monitor cardiac function as increased risk of cardiotoxicity medication Calcium Channel Blockers Plasma concentration of doxorubicin is increased 1 (verapramil) Doxorubicin Ciclosporin Increased risk of neurotoxicity 1 Clozapine Increased risk of agranulocytosis 1 Cytarabine Potential for severe infections and necrosis of intestine CYP3A4 inhibitors Reduction in plasma concentration Cytochrome P450 inducers and May affect doxorubicin metabolism, leading to increased 10 inhibitors toxicity or decreased efficacy Possibility of reduced absorption of oral bioavailability of Digoxin digoxin May increase concentration of epirubicin metabolites when Epirubicin 11 docetaxel administered immediately after epirubicin Hepatotoxic medication Increased risk of hepatoxicity when used in combination 10 (e.g. 6 – mercaptopurine) Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 6 of 28 DRUG INTERACTION WITH INFORMATION REFERENCE Manufacturer advises to leave at least 24 hours between Paclitaxel infusing both drugs as elimination of doxorubicin may be 10 reduced if given within 24 hours of paclitaxel. Doxorubicin (continued) Ritonavir Elevated serum doxorubicin concentration 10 Uric acid lowering agents Doxorubin therapy may lead to an increase in serum uric acid 1 Doxorubicin patients should not be actively vaccinated and also Vaccines 1, 10 avoid contact with recently polio vaccinated patients Cardiotoxic medication Monitor cardiac function as increased risk of cardiotoxicity 11 Ciclosporin Plasma concentration of epirubicin increased by ciclosporin Increases plasma concentration of epirubicin, not explained by 1 Cimetidine CYP activity Clozapine Increased risk of agranulocytosis Dexverapamil Possible increased bone marrow suppression May increase concentration of epirubicin metabolites when Docetaxel Epirubicin docetaxel administered immediately after epirubicin Interferon alpha 2b May reduce total clearance of epirubicin Hepatotoxic medication May affect epirubicin efficacy and toxicity 11, 1 Live vaccines Live vaccines should be avoided Increased risk of toxicity, manufacturers advise at least 24 Paclitaxel hours between infusions if used in combination Quinine Can accelerate distribution of epirubicin into the tissues Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 7 of 28 DRUG INTERACTION WITH INFORMATION REFERENCE Clozapine Increased risk of agranulocytosis Enzyme inducers Increased eribulin plasma concentration Eribulin Inhibitors of hepatic transport May reduce elimination of eribulin and result in up to three fold proteins increase in plasma concentration 12 Eribulin may inhibit CYP3A4, resulting in increased plasma Substrates of CYP3A4 concentration of the substrate. Avoid concomitant use if substrate has narrow therapeutic range. Plasma concentration of erlotinib potentially reduced by Antacids antacids. Give antacids at least 4 hours before or 2 hours after Antivirals (bocepravir) Avoid co-administration 1 Clozapine Increased risk of agranulocytosis Enhanced anticoagulant effect, monitor INR regularly as Coumarins increased risk of bleeding CYP1A2 inhibitors/inducers May alter erlotinib levels 13 CYP3A4 inhibitors/inducers May alter erlotinib levels Erlotinib Avoid concomitant use with cimetidine. Give erlotinib at least 2 H2 receptor antagonists 1 hours before or 10 hours after ranitidine. May reduce plasma concentration-smoking cessation advice Nicotine 13 should be given. NSAIDS Increased risk of bleeding 1 P-glycoprotein inhibitors May alter erlotinib levels 13 May alter erlotinib levels- manufacturers recommend avoid PPIs 1 concomitant use Statins May increase risk of rhabdomyolysis 13 Ref: SACT Interactions Table 4.1 Prepared By J. Allen Checked By S.Williamson/ M.Nagra September 2012 Page 8 of 28 DRUG INTERACTION WITH INFORMATION REFERENCE Atovaquone Increases plasma concentration of etoposide 1 Etoposide clearance may be increased by phenytoin and Antiepileptics phenobarbital 1, 6 Ciclosporin Increased risk of etoposide toxicity with high dose ciclosporin Etoposide 1 Clozapine
Load more

Recommended publications
  • And Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies
    pharmaceuticals Review Micro- and Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies Isabella Portugal 1, Sona Jain 1 , Patrícia Severino 1 and Ronny Priefer 2,* 1 Programa de Pós-Graduação em Biotecnologia Industrial, Universidade Tiradentes, Aracaju 49032-490, Brazil; [email protected] (I.P.); [email protected] (S.J.); [email protected] (P.S.) 2 Massachusetts College of Pharmacy and Health Sciences, University, Boston, MA 02115, USA * Correspondence: [email protected] Abstract: Photodynamic therapy is one of the more unique cancer treatment options available in today’s arsenal against this devastating disease. It has historically been explored in cutaneous lesions due to the possibility of focal/specific effects and minimization of adverse events. Advances in drug delivery have mostly been based on biomaterials, such as liposomal and hybrid lipoidal vesicles, nanoemulsions, microneedling, and laser-assisted photosensitizer delivery systems. This review summarizes the most promising approaches to enhancing the photosensitizers’ transdermal delivery efficacy for the photodynamic treatment for cutaneous pre-cancerous lesions and skin cancers. Additionally, discussions on strategies and advantages in these approaches, as well as summarized challenges, perspectives, and translational potential for future applications, will be discussed. Citation: Portugal, I.; Jain, S.; Severino, P.; Priefer, R. Micro- and Keywords: photodynamic therapy; drug delivery; transdermal; cutaneous; cancer Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies. Pharmaceuticals 2021, 1. Introduction 14, 772. https://doi.org/10.3390/ ph14080772 In past decades, clinical demands for the utilization of photosensitizers (PSs) have increased with the advent of photodynamic therapy (PDT).
    [Show full text]
  • Resolution of Refractory Pruritus with Aprepitant in a Patient With
    Case Report Resolution of refractory pruritus with aprepitant in a patient with microcystic adnexal carcinoma Johanna S Song, MD,ab Hannah Song, BA,a Nicole G Chau, MD,ac Jeffrey F Krane, MD, PhD,ad Nicole R LeBoeuf, MD, MPHabe aHarvard Medical School; bDepartment of Dermatology, Brigham and Women’s Hospital; cCenter for Head and Neck Oncology, Dana-Farber Cancer Institute; dHead and Neck Pathology Service, Brigham and Women’s Hospital; and eCenter for Cutaneous Oncology, Dana-Farber Cancer Institute, all in Boston, Massachusetts ubstance P is an important neurotransmit- biopsied, and the patient was diagnosed with MAC ter implicated in itch pathways.1 After bind- with gross nodal involvement. Laboratory findings ing to its receptor, neurokinin-1 (NK-1), including serum chemistries, blood urea nitrogen, substance P induces release of factors including complete blood cell count, thyroid, and liver func- S 2 histamine, which may cause pruritus. Recent lit- tion were normal. Positron emission tomography- erature has reported successful use of aprepitant, an computed tomography (PET-CT) imaging was NK-1 antagonist that has been approved by the US negative for distant metastases. Food and Drug Administration for the treatment Treatment was initiated with oral aprepitant – of chemotherapy-induced nausea and vomiting, for 125 mg on day 1, 80 mg on day 2, and 80 mg on treatment of pruritus. We report here the case of a day 3 –with concomitant weekly carboplatin (AUC patient with microcystic adnexal carcinoma (MAC) 1.5) and paclitaxel (30 mg/m2) as well as radiation. who presented with refractory pruritus and who had Within hours after the first dose of aprepitant, the rapid and complete resolution of itch after adminis- patient reported a notable cessation in his pruri- tration of aprepitant.
    [Show full text]
  • ULORIC Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------WARNINGS AND PRECAUTIONS-------------------­ These highlights do not include all the information needed to use ULORIC safely and effectively. See full prescribing • Cardiovascular Death: In a CV outcomes study, there was a higher information for ULORIC. rate of CV death in patients treated with ULORIC compared to allopurinol; in the same study ULORIC was non-inferior to ULORIC (febuxostat) tablets, for oral use allopurinol for the primary endpoint of major adverse Initial U.S. Approval: 2009 cardiovascular events (MACE). Consider the risks and benefits of WARNING: CARDIOVASCULAR DEATH ULORIC when deciding to prescribe or continue patients on See full prescribing information for complete boxed warning. ULORIC. (1, 5.1) • Gout patients with established cardiovascular (CV) disease • Gout Flares: An increase in gout flares is frequently observed treated with ULORIC had a higher rate of CV death compared to during initiation of anti-hyperuricemic agents, including ULORIC. If those treated with allopurinol in a CV outcomes study. (5.1) a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti- • Consider the risks and benefits of ULORIC when deciding to inflammatory drug [NSAID] or colchicine upon initiation of prescribe or continue patients on ULORIC. ULORIC should only treatment) may be beneficial for up to six months. (2.4, 5.2) be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to • Hepatic Effects: Postmarketing reports of hepatic failure, allopurinol, or for whom treatment with allopurinol is not sometimes fatal. Causality cannot be excluded.
    [Show full text]
  • Nutrition 102 – Class 3
    Nutrition 102 – Class 3 Angel Woolever, RD, CD 1 Nutrition 102 “Introduction to Human Nutrition” second edition Edited by Michael J. Gibney, Susan A. Lanham-New, Aedin Cassidy, and Hester H. Vorster May be purchased online but is not required for the class. 2 Technical Difficulties Contact: Erin Deichman 574.753.1706 [email protected] 3 Questions You may raise your hand and type your question. All questions will be answered at the end of the webinar to save time. 4 Review from Last Week Vitamins E, K, and C What it is Source Function Requirement Absorption Deficiency Toxicity Non-essential compounds Bioflavonoids: Carnitine, Choline, Inositol, Taurine, and Ubiquinone Phytoceuticals 5 Priorities for Today’s Session B Vitamins What they are Source Function Requirement Absorption Deficiency Toxicity 6 7 What Is Vitamin B1 First B Vitamin to be discovered 8 Vitamin B1 Sources Pork – rich source Potatoes Whole-grain cereals Meat Fish 9 Functions of Vitamin B1 Converts carbohydrates into glucose for energy metabolism Strengthens immune system Improves body’s ability to withstand stressful conditions 10 Thiamine Requirements Groups: RDA (mg/day): Infants 0.4 Children 0.7-1.2 Males 1.5 Females 1 Pregnancy 2 Lactation 2 11 Thiamine Absorption Absorbed in the duodenum and proximal jejunum Alcoholics are especially susceptible to thiamine deficiency Excreted in urine, diuresis, and sweat Little storage of thiamine in the body 12 Barriers to Thiamine Absorption Lost into cooking water Unstable to light Exposure to sunlight Destroyed
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0196469 A1 Thys-Jacobs (43) Pub
    US 2005O196469A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0196469 A1 Thys-Jacobs (43) Pub. Date: Sep. 8, 2005 (54) MICRONUTRIENT SUPPLEMENT (22) Filed: Mar. 4, 2004 COMBINATION FOR ACNE TREATMENT AND PREVENTION Publication Classification (76) Inventor: Susan Thys-Jacobs, Larchmont, NY (51) Int. Cl.' ....................... A61 K 31/59; A61 K 31/525; (US) A61K 33/10; A61K 31/19 (52) U.S. Cl. ......................... 424/687; 514/168; 514/251; Correspondence Address: 514/574 GOTTLEB RACKMAN & REISMAN PC 27O MADSON AVENUE 8TH FLOOR (57) ABSTRACT NEW YORK, NY 100160601 A micronutrient Supplement comprising effective amounts (21) Appl. No.: 10/794,729 of calcium, Vitamin D, and folate treats and prevents acne. US 2005/0196469 A1 Sep. 8, 2005 MICRONUTRIENT SUPPLEMENT COMBINATION therapies include benzoyl peroxide which has comedolytic FOR ACNE TREATMENT AND PREVENTION and antibacterial effects, topical antibacterials Such as eryth romycin or clindamycin, azelaic acid, tazaroc, and topical FIELD OF THE INVENTION retinoids. Acne that is resistant to topical treatment requires oral antibiotics or isotretinoin. Indications for isotretinoin 0001. This invention relates to a micronutrient supple include Severe Scarring, acne that is resistant to oral antibi ment in the treatment of acne Vulgaris and inflammation. In otics and acne present for many years that quickly relapses particular, this invention relates to a multi-vitamin and when an oral antibiotic therapy is discontinued. Of note, oral mineral Supplement for improving skin and hair health. isotretinoin is a potent teratogen. Current Standards of acne therapy include the topical descquarnative drugs and antibac BACKGROUND OF THE INVENTION terial agents.
    [Show full text]
  • Treatment of Head and Neck Cancer with Photodynamic Therapy with Redaporfin: a Clinical Case Report
    Case Rep Oncol 2018;11:769–776 DOI: 10.1159/000493423 © 2018 The Author(s) Published online: November 27, 2018 Published by S. Karger AG, Basel www.karger.com/cro This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. Case Report Treatment of Head and Neck Cancer with Photodynamic Therapy with Redaporfin: A Clinical Case Report Lúcio Lara Santosa, b Júlio Oliveiraa Eurico Monteiroa Juliana Santosa Cristina Sarmentoc aPortuguese Institute of Oncology, Porto, Portugal; bExperimental Pathology and Therapeutics Group of Portuguese Institute of Oncology, Porto, Portugal; cUniversity Hospital of São João, Porto, Portugal Keywords Head and neck cancer · Immunotherapy · Immune checkpoint Inhibitor · Photodynamic therapy · Redaporfin Abstract Advanced head and neck squamous cell carcinoma, after locoregional treatment and multiple lines of systemic therapies, represents a great challenge to overcome acquired resistance. The present clinical case illustrates a successful treatment option and is the first to describe the use of photodynamic therapy (PDT) with Redaporfin, followed by immune checkpoint inhibition with an anti-PD1 antibody. This patient presented an extensive tumor in the mouth pavement progressing after surgery, radiotherapy, and multiple lines of systemic treatment. PDT with Redaporfin achieved the destruction of all visible tumor, and the sequential use of an immune checkpoint inhibitor allowed a sustained complete response. This case is an example of the effect of this therapeutic combination and may provide the basis for a new treatment modality. © 2018 The Author(s) Published by S. Karger AG, Basel Lúcio Lara Santos Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto) Rua Dr.
    [Show full text]
  • HHS Template for Reports, with Instructions
    Texas Vendor Drug Program 1.1 Drug Use Criteria: Substance P/Neurokinin1 Receptor Antagonists Publication History 1. Developed December 2003. 2. Revised September 2020; September 2018; September 2016; May 2015; August 2013; June 2013; September 2011; October 2009; February 2006; January 2006. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document. Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage. Prepared by: • Drug Information Service, UT Health San Antonio. • The College of Pharmacy, The University of Texas at Austin. 1 1 Dosage [*] Current therapies for chemotherapy-induced nausea/vomiting (CINV) and post- operative nausea and vomiting (PONV) target corticosteroid, dopamine, and serotonin (5-HT3) receptors. In the central nervous system, tachykinins and neurokinins play a role in some autonomic reflexes and behaviors. Aprepitant is a selective human substance P/neurokinin 1 (NK1) antagonist with a high affinity for NK1 receptors and little, if any, attraction for corticosteroid, dopamine, or 5-HT3 receptors. Rolapitant (Varubi®), the newest substance P/NK1 antagonist, is FDA- approved to prevent delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults. Combination therapy including netupitant, a substance P/NK1 antagonist and palonosetron, a selective 5-HT3 receptor antagonist (Akynzeo®), is now available to prevent acute and delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Tall Man Lettering List REPORT DECEMBER 2013 1
    Tall Man Lettering List REPORT DECEMBER 2013 1 TALL MAN LETTERING LIST REPORT WWW.HQSC.GOVT.NZ Published in December 2013 by the Health Quality & Safety Commission. This document is available on the Health Quality & Safety Commission website, www.hqsc.govt.nz ISBN: 978-0-478-38555-7 (online) Citation: Health Quality & Safety Commission. 2013. Tall Man Lettering List Report. Wellington: Health Quality & Safety Commission. Crown copyright ©. This copyright work is licensed under the Creative Commons Attribution-No Derivative Works 3.0 New Zealand licence. In essence, you are free to copy and distribute the work (including other media and formats), as long as you attribute the work to the Health Quality & Safety Commission. The work must not be adapted and other licence terms must be abided. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nd/3.0/nz/ Copyright enquiries If you are in doubt as to whether a proposed use is covered by this licence, please contact: National Medication Safety Programme Team Health Quality & Safety Commission PO Box 25496 Wellington 6146 ACKNOWLEDGEMENTS The Health Quality & Safety Commission acknowledges the following for their assistance in producing the New Zealand Tall Man lettering list: • The Australian Commission on Safety and Quality in Health Care for advice and support in allowing its original work to be either reproduced in whole or altered in part for New Zealand as per its copyright1 • The Medication Safety and Quality Program of Clinical Excellence Commission, New South
    [Show full text]
  • Chapter 1.Pdf
    CHAPTER 1 INTRODUCTION AND OUTLINE OF THIS THESIS INTRODUCTION Inflammatory bowel diseases (IBD), comprising Crohn’s disease, ulcerative colitis and IBD- 1 unclassified, are chronic recurrent inflammatory disorders of the (large) intestine with a heterogeneous, but often disabling disease presentation. The prevalence of IBD is increasing worldwide and medical therapies are introduced earlier to improve health-related quality of life and postpone surgical interventions1,2. This has led to the more extensive use of immunosuppressive therapies including biologicals and thiopurines. While the use of tioguanine was soon abandoned due to toxicity concerns3, over the years efficacy data on the use of azathioprine and mercaptopurine for the treatment of IBD has grown4,5. However, due to side effects and ineffectiveness, related to unprofitable metabolism, thiopurine therapy often fails; up to 50% of patients discontinues treatment within 2 years6. Increasing the knowledge on thiopurine metabolism may provide opportunities to further explore the therapeutic usefulness of thiopurines, which both from a patient’s perspective and a pharmacoeconomic perspective is essential. THIOPURINES In the 1950’s Gertrude Elion (1918-1999) worked as an assistant to George Hitchings (1905- 1998), both employees of Burroughs-Wellcome, focussing on the advent of drugs that inhibited cell growth without doing harm to the host cells. They discovered that purine bases are essential components of nucleic acids and vital for cell growth7. Subsequently, they designed the purine antagonists diaminopurine and tioguanine that blocked the synthesis of original nucleic acids and inhibited cell growth8. For the first time a successful treatment of leukaemia became available. Some years later Elion and colleagues also developed mercaptopurine, azathioprine, allopurinol, trimethoprim and acyclovir.
    [Show full text]
  • WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: A61K 31/53 (2006 .01) A61P 35/00 (2006 .0 1) C07D 251/40 (2006.01) (21) International Application Number: PCT/US20 18/024 134 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,585 24 March 2017 (24.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Devenport Av enue, Berkeley, CA 94619 (US). ANDERSON, Kimberly, E.; 8 Marchant Court, Kensington, CA 94707 (US). (74) Agent: LEE, Joohee et al; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 021 11 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Gastroparesis: 2014
    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
    [Show full text]